Founder and CEO
Jeffrey Wolf is founder and CEO of Heat Biologics, and co-founder of Pelican Therapeutics. He also founded Seed-One Ventures and served as managing director for the company, which was focused on the systematic formation and management of new biomedical companies based upon novel research breakthroughs.
Throughout his career, Mr. Wolf has specialized in building life-science startup organizations, and has played an active role in supporting the growth of his companies. Mr. Wolf's start-ups include Avigen (co-founder and director), a NASDAQ-listed gene therapy company; TyRx Pharma (co-founder and Chairman), which was focused on the development of novel bio-compatible polymers and recently sold to Medtronic; EluSys Therapeutics (founder and CEO), focused on the development of novel antibodies against infectious diseases; and GenerationOne (founder and CEO), a mobile-based healthcare solutions company.
Mr. Wolf received his MBA from Stanford Business School, his JD from New York University School of Law and his BA from the University of Chicago, where he graduated with honors in Economics.
Jeff Hutchins, Ph.D.
Chief Scientific Officer and Senior Vice President, Pre-clinical Research, Heat Biologics and Pelican Therapeutics
As Chief Scientific Officer and Senior Vice President, Pre-clinical Development, Jeff Hutchins oversees the research and development efforts for Heat Biologics, as well as for the company’s subsidiary, Pelican Therapeutics. He brings more than 24 years of research and clinical development experience from both pharmaceutical- and biotechnology-focused companies. Most recently, Dr. Hutchins served as Vice President of Pre-clinical Research for Peregrine Pharmaceuticals, Inc., a biopharmaceutical company developing therapeutics to fight cancer and infectious diseases. Dr. Hutchins was responsible for building out the research program for Peregrine's lead product candidate, bavituximab, a chimeric monoclonal antibody designed to target phosphatidylserine.
Prior to joining Peregrine in 2012, Dr. Hutchins served as Vice President, Preclinical Development at Inhibitex Inc, which was acquired by Bristol-Myers Squibb. From 1991 to 2000, Dr. Hutchins held several senior scientist positions in Discovery Research at Burroughs Wellcome and Glaxo Wellcome, with a visiting professor appointment at Rush Medical College.
Dr. Hutchins earned his Ph.D. in Biomedical Sciences from the University of Texas, Health Science Center at the M.D. Anderson Cancer Center, followed by postdoctoral training in the University of Southern California's Department of Microbiology at the Norris Cancer Center. Dr. Hutchins' publications and patents span the fields of oncology, infectious disease, osteoarthritis and immunology. He received his B.S. in Biology from Oral Roberts University.
George Peoples, M.D., FACS
Chief Medical Officer
U.S. Army, COL (ret) George E. Peoples, M.D., FACS serves as Heat's Chief Medical Officer. Dr. Peoples recently retired from 30 years of active duty as a surgeon and research scientist in the military. He is the Founder and Director of Cancer Insight, LLC, a clinical research and development organization dedicated to the discovering, developing and testing for emerging biotechnologies specializing in cancer immunotherapy. Dr. Peoples is a Professor of Surgery at Uniformed Services University of the Health Sciences and a Professor (adjunct) of Surgical Oncology at MD Anderson Cancer Center (MDACC). He is the past Chair of the Cancer Program, San Antonio Military Medical Center and the past Deputy Director of the United States Military Cancer Institute. Dr. Peoples served as the Chief of Surgical Oncology at Walter Reed Amy Medical Center (WRAMC) from 1998 to 2006 and at SAMMC from 2006 to 2014. He is a graduate of the United States Military Academy, West Point and the Johns Hopkins School of Medicine. He completed his surgical training at Harvard's Brigham and Women's Hospital, and during that time, also completed a postdoctoral fellowship at the Laboratory of Biologic Cancer Therapy at Harvard Medical School. He then completed a surgical oncology fellowship at MDACC before becoming Chief of Surgical Oncology at WRAMC. He has written extensively on the immune response to cancer with over 300 peer-reviewed manuscripts, abstracts and book chapters.
Ann Rosar, M.B.A.
Vice President of Finance, Corporate Secretary
Ann Rosar has more than 20 years of finance experience within publicly held companies and more than 15 years of experience focusing on regulatory reporting requirements. Prior to serving as VP of Finance at Heat Biologics, Ms. Rosar served as Manager of Financial Reporting and Accounting for LipoScience, Inc. (acquired by LabCorp), a provider of specialized cardiovascular diagnostic tests, from 2013 to 2015. She also held various roles from 2007 to 2013 at the oncology supportive care pharmaceutical company, DARA Biosciences, Inc. (now Midatech Pharma US), including VP of Finance, Chief Accounting Officer and Controller. Earlier in her career, Ms. Rosar had also been responsible for Securities and Exchange Commission reporting, audits and budget analysis at the business integration software provider, Cicero, Inc. (formerly Level 8 Systems); as well as Senior Financial Analyst-Business Operations for Nextel Communications.
Ms. Rosar received an MBA in Finance from the University of Houston and received her undergraduate degree from North Carolina State University.
Vice President, CMC
As Vice President of Chemistry and Manufacturing Controls, Gary Vinson is responsible for all manufacturing and analytical development for Heat Biologics, as well as for the company's subsidiary, Pelican Therapeutics.
He has more than 20 years of experience in the pharmaceutical, CRO/CMO and biotechnology industries, in technical, development and quality roles. Prior to joining Heat, he held roles as Vice President, Pharmaceutical Development at a specialty pharmaceutical company, BioDelivery Sciences, and at Aldagen, a clinical-stage regenerative medicine company developing adult cell therapies. His responsibilities have included leading manufacturing, analytical development and quality organizations, and he has significant experience developing CDMO outsourcing relationships from pre-IND through to registration. Mr. Vinson founded and was Managing Partner of The Perdoceo Group, LLC, a consulting firm providing CMC support to biotechnology and pharmaceutical clients. He began his career with Glaxo, Inc. and worked at Magellan Laboratories, where he was a principal in establishing the pharmaceutics group to provide contract development and manufacturing of clinical trial materials. He received his B.S. In Chemistry from North Carolina State University and holds CPGP (Certified GMP Professional) and RAC (Regulatory Affairs Certification) certifications.